- Trials with a EudraCT protocol (575)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
		
	   		
	   		    
                    
                   	
                   	    575 result(s) found for: Salpingectomy.
                    
                
			
   			
		
		Displaying page 1 of 29.
	
	
	| EudraCT Number: 2016-001577-33 | Sponsor Protocol Number: D24-DIPG | Start Date*: 2016-11-03 | 
| Sponsor Name:Clínica Universidad de Navarra | ||
| Full Title: Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. | ||
| Medical condition: Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-003896-20 | Sponsor Protocol Number: 3667 | Start Date*: 2013-02-14 | 
| Sponsor Name:The Royal Marsden NHS Foundation Trust [...] | ||
| Full Title: TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours | ||
| Medical condition: Solid tumours | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-004230-37 | Sponsor Protocol Number: BCX7353-312 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||
| Full Title: An open-label study to provide berotralstat access to subjects with type 1 and 2 hereditary angioedema who were previously enrolled in berotralstat studies | |||||||||||||
| Medical condition: Hereditary Angioedema | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005185-18 | Sponsor Protocol Number: HEPA-CRV431-207 | Start Date*: 2022-07-13 | |||||||||||
| Sponsor Name:Hepion Pharmaceuticals, Inc. | |||||||||||||
| Full Title: ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVAN... | |||||||||||||
| Medical condition: NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001582-25 | Sponsor Protocol Number: D7550C00003 | Start Date*: 2017-09-29 | 
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A 4-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 in patients with coronary artery ... | ||
| Medical condition: Coronary artery disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) DK (Completed) FI (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-012094-35 | Sponsor Protocol Number: D5090C00018 | Start Date*: 2009-08-11 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment... | |||||||||||||
| Medical condition: Patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN) Intended Indication is Neuropathic Pain | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) FR (Completed) DK (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002690-19 | Sponsor Protocol Number: D9150C00003 | Start Date*: 2017-12-14 | 
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A randomized, double-blind, placebo-controlled, multi-centre, sequential design, phase IIa study to evaluate safety and tolerability of epicardial injections of AZD8601 during coronary bypass graf... | ||
| Medical condition: Heart failure | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) NL (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-001863-21 | Sponsor Protocol Number: FIOL | Start Date*: 2018-08-14 | 
| Sponsor Name:Vestre Viken Hospital Trust | ||
| Full Title: First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies. | ||
| Medical condition: Lung cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Trial now transitioned) LT (Trial now transitioned) DK (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-001586-87 | Sponsor Protocol Number: RSLV-132-04 | Start Date*: 2016-09-29 | 
| Sponsor Name:Resolve Therapeutics, LLC | ||
| Full Title: A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome | ||
| Medical condition: Primary Sjogrens Syndrome | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-006968-11 | Sponsor Protocol Number: AP214-CS005 | Start Date*: 2009-04-21 | |||||||||||
| Sponsor Name:Action Pharma A/S | |||||||||||||
| Full Title: Pharmacokinectics of AP214 Acetate in patients undergoing cardiac surgery. A randomized, double-blind, placebo-controlled sequential ascending dose trial investigating pharmacokinetics, as well as... | |||||||||||||
| Medical condition: Action Pharma A/S is developing AP214 Acetate for the prevention of postsurgical kidney injury after thoracic aortic aneurysm repair surgery. In phase 2: Patients undergoing cardiac surgery, defin... | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003232-36 | Sponsor Protocol Number: GN16ST187 | Start Date*: 2017-12-20 | |||||||||||
| Sponsor Name:NHS Greater Glasgow & Clyde [...] | |||||||||||||
| Full Title: Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial with GOLD Imaging Theranostic (POST-IT) | |||||||||||||
| Medical condition: Acute ischaemic stroke | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-000701-13 | Sponsor Protocol Number: ISIS494372-CS3 | Start Date*: 2014-08-07 | |||||||||||
| Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously t... | |||||||||||||
| Medical condition: High Lipoprotein(a) | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (Completed) DK (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-001095-77 | Sponsor Protocol Number: AC4105211 | Start Date*: 2008-09-19 | 
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
| Full Title: A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 form... | ||
| Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | ||
| Disease: | ||
| Population Age: | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-002172-40 | Sponsor Protocol Number: ISIS426115-CS2 | Start Date*: 2014-01-08 | |||||||||||
| Sponsor Name:Isis Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutane... | |||||||||||||
| Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001046-19 | Sponsor Protocol Number: ORA-D-N01B | Start Date*: 2020-08-13 | 
| Sponsor Name:Oramed Ltd. | ||
| Full Title: An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH) | ||
| Medical condition: Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-001899-32 | Sponsor Protocol Number: RESINFENOL | Start Date*: 2017-08-17 | 
| Sponsor Name:Dr. Abelardo Aguilera Peralta | ||
| Full Title: Crossover and randomized clinical trial on the effect of Resincolestiramine in the intestinal absorption of new uremic toxins in patients in hemodialysis with chronic renal insufficiency | ||
| Medical condition: Chronic renal insufficiency | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-005013-76 | Sponsor Protocol Number: AC15004 | Start Date*: 2016-04-13 | |||||||||||
| Sponsor Name:ACCORD office [...] | |||||||||||||
| Full Title: GEM3: A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy | |||||||||||||
| Medical condition: Ectopic pregnancy | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2023-000381-34 | Sponsor Protocol Number: CL019_168 | Start Date*: 2023-05-30 | 
| Sponsor Name:ChemoCentryx | ||
| Full Title: An Open Label, Randomized, Crossover, Single Dose Bioavailability Study in Healthy Adult Subjects to Evaluate the Pharmacokinetic Profile of an Exploratory Avacopan Pediatric Liquid Formulation Com... | ||
| Medical condition: Anti-Neutrophil Cytoplasmic Antibody associated vasculitis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2019-004207-13 | Sponsor Protocol Number: Toco-CoR | Start Date*: 2019-12-11 | |||||||||||
| Sponsor Name:Vejle Hospital | |||||||||||||
| Full Title: Tocotrienol and Bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial | |||||||||||||
| Medical condition: | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-006810-35 | Sponsor Protocol Number: Glioma_Theranostics | Start Date*: 2022-11-02 | 
| Sponsor Name:Norwegian University of Science and Technology | ||
| Full Title: 68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma | ||
| Medical condition: Patients with confirmed recurrent grade 3 and grade 4 glioma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Trial now transitioned) | ||
| Trial results: (No results available) | ||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
 .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
 Query did not match any studies.
    	Query did not match any studies.
     
				
